Targeting Inflammation and Fibrosis in Cardiovascular Disease: Emerging Mechanisms and Therapies
The FASEB Journal · 15.09.2025 · 39 (17)
DOI: 10.1096/fj.202500970r ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The FASEB Journal, online erschienen am 09.09.2025. Verfasst von Hector A Cabrera-Fuentes und 6 weiteren Autor:innen. Beteiligte Einrichtung: División de Estudios de Posgrado e Investigación, Tecnológico Nacional de México/Instituto Tecnológico de Tijuana, Tijuana, México. Hauptthemen laut MEDLINE: Inflammation, Fibrosis, Cardiovascular Diseases. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 106 Literaturangaben. Gefördert von: Romanian Ministry of Education and Research.
Abstract (Originalsprache)
Cardiovascular diseases are increasingly recognized as chronic disorders driven by a complex interplay between inflammation and fibrosis. In this review, we elucidate emerging mechanisms that govern the transition from acute inflammation to pathological fibrosis, with particular focus on cellular crosstalk between neutrophils, macrophages, fibroblasts, and myofibroblasts. We explore how dysregulated immune responses and extracellular matrix (ECM) remodeling sustain a pathogenic feedback loop, promoting myocardial stiffening and adverse cardiac remodeling. Special attention is given to the plasticity of immune and stromal cells, including macrophage polarization and fibroblast‐to‐myofibroblast transitions, as well as the roles of TGF‐β signaling, hypoxia, and noncoding RNAs. Building on this mechanistic foundation, we highlight next‐generation therapeutic strategies—ranging from immunometabolic and epigenetic reprogramming to gene editing, cell‐based therapies, and nanomedicine—designed to interrupt the inflammation–fibrosis axis. By targeting these interconnected pathways, emerging therapies offer the potential to reverse maladaptive remodeling, restore cardiac function, and redefine the treatment landscape in cardiovascular disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- División de Estudios de Posgrado e Investigación, Tecnológico Nacional de México/Instituto Tecnológico de Tijuana, Tijuana, México.
- R&D Group, Vice Presidency Scientific Research & Innovation, Imam Abdulrahman Bin Faisal University (IAU), Dammam, Saudi Arabia.
- Dirección de la División de Investigación y Desarrollo Científico, Benemérita Universidad de Oaxaca, Oaxaca, México.
- UNAM-UABJO Research Center, Faculty of Medicine and Surgery, Universidad Autonoma "Benito Juárez" de Oaxaca (UABJO), Oaxaca, México.
- CNRS, Laboratoire IMoPA, UMR 7365, Université de Lorraine, Nancy, France.
- División de Estudios de Posgrado e Investigación, Tecnológico Nacional de México/Instituto Tecnológico de Oaxaca, Oaxaca, Mexico.
ORCID-Profile: Hector A Cabrera-Fuentes, Guillermo Barreto, Eduardo Perez-Campos, Gilka F Nivon-Torres, Aldo Abel Garcia González, Ebtesam Abdullah Al-Suhaim, Elisa A Liehn
Förderung
- Romanian Ministry of Education and Research
Zitieren
APA
Cabrera-Fuentes, H. A., Barreto, G., Perez-Campos, E., Nivon-Torres, G. F., Garcia González, A. A., Al-Suhaim, E. A., & Liehn, E. A. (2025). Targeting Inflammation and Fibrosis in Cardiovascular Disease: Emerging Mechanisms and Therapies. The FASEB Journal, 39(17). https://doi.org/10.1096/fj.202500970r
Vancouver
Cabrera-Fuentes HA, Barreto G, Perez-Campos E, Nivon-Torres GF, Garcia González AA, Al-Suhaim EA, et al. Targeting Inflammation and Fibrosis in Cardiovascular Disease: Emerging Mechanisms and Therapies. The FASEB Journal. 2025;39(17). doi:10.1096/fj.202500970r
BibTeX
@article{CabreraFuentes2025,
author = {Cabrera-Fuentes, Hector A and Barreto, Guillermo and Perez-Campos, Eduardo and Nivon-Torres, Gilka F and Garcia González, Aldo Abel and Al-Suhaim, Ebtesam Abdullah and Liehn, Elisa A},
title = {Targeting Inflammation and Fibrosis in Cardiovascular Disease: Emerging Mechanisms and Therapies},
journal = {The FASEB Journal},
year = {2025},
volume = {39},
number = {17},
doi = {10.1096/fj.202500970r}
}
EUVIMED